Synthetic Biologics, Inc. (SYN)

NYSE American - NYSE American Delayed Price. Currency in USD

Add to watchlist

Visitors trend2W10W9M

1.4200

+0.0300

(+2.16%)

At close: 04:00PM EDT

1.4900

+0.07

(+4.93%)

After hours:

05:43PM EDT

Advertisement

Full screen

Trade prices are not sourced from all markets

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Neutralpattern detected

View all chart patterns

Performance Outlook

Previous Close	1.3900
Open	1.4600
Bid	1.4200 x 1200
Ask	1.4400 x 800
Day's Range	1.3600 - 1.4900
52 Week Range	1.3500 - 5.6000
Volume	334,987
Avg. Volume	188,075

Market Cap	187.501M
Beta (5Y Monthly)	1.55
PE Ratio (TTM)	N/A
EPS (TTM)	-0.2240
Earnings Date	Mar 02, 2022 - Mar 07, 2022
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	16.25

All

GlobeNewswire
Synthetic Biologics to Participate in the BTIG Biotechnology Conference 2022
ROCKVILLE, Md., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, today announced that Company’s management will participate in one-on-one investor meetings at the BTIG Biotechnology Conference 2022, to be held virtually and in New York City from August 8-9, 2022. BTIG hosted events are intended for prospective and existing BTIG clients only. To sch
- Q4 Inc. Announces Appointment of Chief Financial Officer
  Business Wire
- Moody’s Corporation Posted an Updated Management Presentation for Investors
  Business Wire
GlobeNewswire
Synthetic Biologics to Host Conference Call and Webcast to Discuss Second Quarter 2022 Operational Highlights and Financial Results
ROCKVILLE, Md., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, today announced that it plans to host a conference call on Thursday, August 11, 2022, at 8:30 a.m. ET to discuss its financial results for the quarter ended June 30, 2022 and provide a corporate update. Individuals may participate in the live call via telephone by dialing (800) 289-05
GlobeNewswire
Synthetic Biologics Announces $3 Million Private Placement of Convertible Preferred Stock
ROCKVILLE, Md., July 29, 2022 (GLOBE NEWSWIRE) -- Synthetic Biologics, Inc.. (NYSE American: SYN) (“Synthetic Biologics” or the “Company”), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, today announced the private placement of 275,000 shares of Series C convertible preferred stock and 100,000 shares of Series D convertible preferred stock. Each share of Series C and Series D preferred stock has a purchase price of $8.00. Each